In fact, simultaneous therapy using PD-1 inhibitors and targeting the adenosine pathway was more effective in improving survival, reducing tumor growth, and limiting metastasis than single therapy in some types of cancer (106–108). This evidence concerns the gene PDCD1 and cancer.